Crispr Therapeutics Ag (CRSP)

EBITDA Growth

45.45%

Quarterly · Period ending:

CRSP logo

CRSP EBITDA Growth

Year-over-year change vs the same period a year earlier

Latest reported45.45%
CRSP Quarterly EBITDA YoY % (-214.13% → 45.45%)
High-resolution chart · PNG

CRSP ebitda growth history

Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.

Crispr Therapeutics Ag EBITDA Growth — Quarterly
Period endingEBITDA Growth
45.4533%
9.5105%
-291.3815%
-26.2203%
-68.4526%
-17.2172%
-133.6251%
24.798%
-67.3848%
-137.7907%
182.7284%
37.2068%
58.3315%
72.4633%
13.9595%
-38.9482%
-122.4827%
-51.6347%
-26.179%
-35.93%
1,077.1342%
-56.4137%
-947.3218%
-164.1271%
-45.9459%
-50.1649%
124.326%
389.2871%
-47.6758%
-81.9227%
-2,970.4162%
-113.1399%
-76.801%
-30.6982%
107.7649%
-57.6441%
-21.2264%
-71.2624%
-89.8988%
-134.8285%
-370.5899%
-214.1322%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.